TABLE 1.
Summary of Treatment‐Induced Immunological Alterations and the Pretreatment Levels of HBV, Tumor, and Inflammatory Markers Detected in the Peripheral Blood Compartment of All Treated Patients
| Patient No. | HBV‐TCRs | Treatment‐Induced Immunological Alterations | Pretreatment Levels | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Events (Y/N) | T‐cell Activation Response | Serum chemokine Response | Radiological Response | HBV Virological Response | HBsAg (IU/mL) | ALT (IU/L) | CRP (mg/L) | PLR | NLR | LMR | ||
| B001 | HBV‐Env HLA‐A0201 restricted | Y | + | − | + | <LLOD | 202 | 26 | 30.2 | 153.89 | 2.53 | 5.57 |
| B008 | HBV‐Env HLA‐A0201 restricted | N | + | + | + | <LLOD | 303.8 | 14 | 3.5 | 81.52 | 2.44 | 4.72 |
| B005 | HBV‐Env HLA‐A0201 restricted | N | − | + | ±* | <LLOD | 942.6 | 26 | 2.4 | 83.33 | 1.31 | 7.38 |
| B002 | HBV‐Env HLA‐A0201 restricted | Y | − | − | ± | + | 1444 | 32 | 1.6 | 30.59 | 2.01 | 4.05 |
| B003 | HBV‐Env HLA‐A0201 restricted | N | − | − | − | <LLOD | 929.9 | 40 | 5.9 | 81.91 | 2.90 | 4.70 |
| B004 | HBV‐Env HLA‐Cw0801 restricted | N | − | − | − | <LLOD | 210.9 | 48 | 48.6 | 326.42 | 4.87 | 2.52 |
| B006 | HBV‐Env HLA‐A0201 restricted | N | − | − | − | <LLOD | 1549 | 20 | 9.3 | 166.07 | 3.24 | 3.86 |
| B007 | HBV‐Env HLA‐A0201 restricted | N | − | − | − | <LLOD | 231.5 | 28 | 126.8 | 313.64 | 7.15 | 2.20 |
Abbreviations: LLOD, lower limit of detection; N, no; Y, yes.
*
Both target lesions remain stable during therapy.